Keith R. Alexandra 4

What Happened Keith R. Alexandra, a director of Thermo Fisher Scientific (TMO), received a grant/award of 499 shares on May 20, 2026. The Form 4 reports the acquisition price as $0.00 (total reported acquisition value $0), which typically indicates a compensation grant (e.g., restricted stock or RSUs) rather than an open-market purchase.

Key Details

• Transaction date: 2026-05-20; Reported on Form 4 filed 2026-05-22.
• Transaction type/code: A = Award/Grant (499 shares acquired at $0.00).
• Reported acquisition value: $0 (price per share $0.00 as listed on Form 4).
• Shares owned after transaction: not specified in the summary provided (check the full Form 4 for total holdings).
• Footnotes/plan details: none provided in the summary here; no 10b5-1 plan or tax-withholding entries listed.
• Filing timeliness: Filed two days after the transaction date (appears timely under Form 4 two-business-day rule).

Context Awards to directors are typically part of compensation (e.g., annual equity retainer or restricted stock units) and do not necessarily signal a personal market view. Such grants may vest over time or be subject to restrictions; consult the full Form 4 or company proxy for vesting and plan details if you need to assess potential future share sales or dilution.